Cáncer de mama precoz: el caso de la neoadyuvancia en HER2 positivo - page 45

HR=0.76 (95% CI: 0.67-0.86)
% Event -Free
60
40
20
0
0 2 4 6 8 10
P<0.0001
0 1 2 3 4 5
Without T With T
100
80
???% 28.8%
% Event -Free
60
40
20
0
100
80
Years from Randomization
Without T With T
Years from Randomization
Neoadjuvant
PERTUZUMAB
Event-Free Survival
L. Gianni et al, ASCO Annual Meeting 2013
Adjuvant
HERA
Disease-Free Survival
Roche data on file.
With P
Neoadjuvant key messages